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Abstract

Author Manuscript

Methadone is a synthetic, long-acting opioid with a single chiral center forming two enantiomers,
(R)-methadone and (S)-methadone, each having specific pharmacological actions. Concentrations
of (R)- and (S)-methadone above therapeutic levels have the ability to cause serious, lifethreatening, and fatal side effects. This toxicity can be due in part to the pharmacogenetics of an
individual, which influences the pharmacokinetic and pharmacodynamic properties of the drug.
Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes,
predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18,
3A7, 2C8, 2C9, 3A5, and 1A2. Single nucleotide polymorphisms (SNPs) located within CYPs
have the potential to play an important role in altering methadone metabolism and
pharmacodynamics. Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in
increases in methadone plasma concentrations, decreased N-demethylation, and decreased
methadone clearance. In particular, carriers of CYP2B6*6/*6 may have a greater risk for
detrimental adverse effects, as methadone metabolism and clearance are diminished in these
individuals. CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations
of methadone due to increased methadone clearance. The involvement, contribution, and
understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can
improve the therapeutic uses of methadone in patient outcome and the development of
personalized medicine.
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1.

Methadone pharmacology
Shortly after methadone was introduced in the United States, the Food and Drug
Administration (FDA) approved its use as an analgesic and antitussive agent [1]. During the
1960s, evidence for the usefulness of methadone in the treatment of and maintenance
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therapy for narcotic addiction was growing [2,3]. A decade later, the FDA expanded the
approval for physicians and hospital pharmacies to dispense methadone for treating opiate
addiction in treatment programs only [1]. Enrollment in a methadone maintenance treatment
(MMT) program also has the potential to be a public health strategy for decreasing the
transmission of infectious diseases (e.g. HIV/AIDS, hepatitis C, or other blood-borne
pathogens) by reducing the number of opioid users reusing contaminated needles [3–5].

Author Manuscript

Methadone is a synthetic, long-acting opioid with a single chiral center that forms two
enantiomers, R-(−)-methadone (levo-methadone) and S-(+)-methadone (dextro-methadone)
[6,7]. Both enantiomers have specific pharmacodynamic properties and pharmacological
actions. (R)-Methadone is a μ-opioid receptor (MOR) agonist that mimics the body’s natural
endogenous opioids, endorphins and enkephalins.Binding of (R)-methadone to the MOR
mediates therapeutic effects with the release of other neurotransmitters, including
acetylcholine, dopa-mine, norepinephrine, and substance P [6]. The effects propagated by
this interaction yields reduction and elimination of drug cravings and withdrawal signs and
symptoms of narcotics, analgesia, sedation, nausea, vomiting, constipation, miosis,
antitussive effects, hypotension, mild bradycardia, and tolerance and dependence [8–11].
In the United States, methadone is clinically available only as a racemic formulation
comprised of both (R)- and (S)-methadone enantiomers [12–14]. Methadone is currently
used as: (1) an approved opioid substitution therapeutic agent to suppress opioid-abstinence
syndrome in opiate abuse and addiction [15–19]; (2) a second-line opioid in alleviating
cancer pain and chronic non-malignant pain, such as back, joint, or neuropathic pain and
other forms of severe pain [20–23]; and (3) a first-line treatment in patients with both opioid
dependence and chronic pain [24].

Author Manuscript

Methadone has contributed to a significant portion of opioid-related overdose deaths.
However, this outcome is not attributed to the use of methadone for opioid dependence,
rather from prescriptions of methadone for pain management [25]. Reports from the Centers
for Disease Control and Prevention (CDC) indicate a 15.6% increase in opioid death rates
from 2014 to 2015. Conversely, methadone death rates decreased by 9.1% due to factors
such as efforts to reduce methadone therapy for pain, warning labels, clinical guidelines, and
limiting high dose formulations [26]. However, death rates continued to increase through
2014 resulting from methadone overdosing in individuals between the ages of 55–64 years
[25].

Author Manuscript

Concentrations of (R)- and (S)-methadone above therapeutic levels have negative and
detrimental side effects. Elevated (R)-methadone levels may depress ventilation, inducing
respiratory depression, by acting on the MORs expressed on respiratory centers in the
brainstem [27–29]. Conversely, an increase in (S)-methadone disposition causes
cardiotoxicity through the blockage of the voltage-gated potassium channel of the human
ether-a-go-go related gene (hERG), subsequently prolonging the QT interval of an
electrocardiogram leading to torsades de pointes. (S)-Methadone is 3.5 times more potent
than (R)-methadone in blocking the hERG channel, thus attributing the stereoselectivity of
methadone to cardiotoxicity [30–33].
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Methadone is primarily eliminated via hepatic metabolism by cytochrome P450 (CYP)
enzymes through oxidative biotransformation. Methadone undergoes stereoselective Ndemethylation followed by spontaneous cyclization to form the principle, inactive metabolite
2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (Fig. 1) [34–39].Methadone has a
broad half-life of elimination ranging from 5 to 130 h, with an average of 22 h [40]. This
extreme inconsistency in the elimination half-life exemplifies the large variability
methadone possesses in its pharmacokinetics between individuals. Because of the interindividual variation, it is difficult to predict an individual’s peak plasma levels, which may
result in some individuals having a higher than normal plasma level that approaches the
toxic or even fatal drug concentration. Co-medication, age, gender, health, weight, and
ethnicities can all be factors that contribute to this effect.

Author Manuscript

Genetic variation occurs within and among populations, leading to polymorphisms. Single
nucleotide polymorphisms (SNPs) are the most common type of genetic variation. A SNP is
a variation of a single nucleotide at a specific position in the genome, some of which may
contribute to changes in a gene, either in the coding (exons) or non- coding (introns) regions,
or the regions between genes. A genetic variation within CYP genes responsible for the
metabolism of methadone may be causal for altered function, which may result in
methadone being rapidly eliminated from the body, thus preventing the drug from reaching
therapeutic levels. Alternatively, the genetic variation may prolong elimination from the
body, consequently, intensifying analgesic and detrimental adverse effects [41,42]. The
purpose of this review is to focus on the effects of SNPs of the various CYPs that metabolize
methadone.

2.

Methadone metabolism

Author Manuscript

Eleven metabolites from methadone metabolism have been isolated and identified in urine
and feces in humans [43]. Methadone predominantly forms the pharmacologically inactive
pyrrolidine metabolites EDDP and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP).
Methadol and normethadol are active analgesic metabolites of methadone, although this
pathway is relatively minor [44,45]. To a lesser extent, methadone, normethadol, EDDP, and
EMDP are further hydroxylated to form inactive p-hydroxy metabolites. Another minor
pathway yields the inactive metabolites 4-dimethylamino-2,2-diphenylvaleric acid, 4methylamino-2,2-diphenylvaleric acid, and 1,5-dimethyl-3,3-diphenyl-2-pyrrolidone (Fig. 1)
[43–45].

Author Manuscript

The CYP enzymes involved in the formation of methadone meta-bolites in humans are
CYP2B6, 3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2
[46]. These CYPs, however, metabolize methadone in a stereoselective manner, where
CYP2C19, 3A7, and 2C8 preferentially metabolize (R)-methadone, CYP2B6, 2D6, and
2C18 primarily metabolize (S)-methadone, and CYP3A4 demonstrates no stereoselectivity
in methadone metabolism [46,47]. Methadone is N-demethylated to an intermediate
compound, normethadone, which is then spontaneously cyclized to form EDDP. A second
N-demethylation reaction occurs on EDDP to form EMDP [35–37,44,48]. An alternate
metabolic pathway in the formation of EMDP is a CYP mediated N-demethlyation of
normethadone to form dinormethadone, which is then spontaneously cyclized to EMDP
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[47]. In a minor bio-transformation pathway, the keto group of methadone is reduced by
alcohol dehydrogenase to form methadol, which can be N-demethylated to form
normethadol. The inactive (S)-methadone produces active metabolites of α-l-methadol and
α-l-normethadol, which have analgesic properties comparable to (R)-methadone. (R)Methadone, on the other-hand, is metabolized to biologically inactive metabolites of dmethadol and d-normethadol [44,45,47].
Methadone’s long ranging half-life can be partially attributed to the extreme interindividual
pharmacokinetics and its stereoselective metabolism [49,50]. (S)-Methadone exhibits a
significantly shorter elimination half-life than (R)-methadone [48,51]. Inherited
polymorphisms in CYPs have the potential to affect the metabolic rate of methadone in a
stereoselective manner. The following sections will discuss the role of CYP SNPs in
methadone metabolism and its consequences on biological activity.

Author Manuscript

3.

Cytochrome P450 (CYP)

Author Manuscript

There are approximately 57 active human CYP genes grouped into 18 families and 44
subfamilies. Only 12 CYP enzymes, which belong to the CYP1, CYP2, or CYP3 families,
are of major importance and responsible for the metabolism of more than 95% of therapeutic
drugs [52–54]. The involvement and contribution of SNPs is inadequately understood in
drug biotransformation, but are known to play a vital role in the differences in patient
outcome and the development of personalized medicine [55]. SNPs can cause a loss of
function mutation, in which the splicing, expression, or transcription of the CYP gene is
decreased or the protein structure is altered. Alternatively, gain of function mutations may
also occur, resulting in an increased substrate turnover due to an increased number of
functional gene copies, as well as variations in the promotor or amino acids [54,56,57].
SNPs may be responsible for determining metabolic phenotype – ultra-rapid metabolizers
(UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor
metabolizers (PMs) – and the binding affinity to CYPs, all while affecting the half-life, as
well as the therapeutic and detrimental effects of methadone.
3.1.

CYP1 family
The CYP1 family consists of two subfamilies, encompassing three functional genes,
CYP1A1, 1A2, and 1B1. CYP1A1 and CYP1B1 enzymes are mainly expressed extrahepatically, whereas CYP1A2 accounts for 4–16% of the hepatic CYPs and is responsible
for 8–10% of the drugs metabolized by CYP isoforms, including methadone [41,54,58].

Author Manuscript

The interindividual variations in the mRNA and protein expression levels of CYP1A2 range
from 15 to 40 fold, and a 40–130 fold inter-individual difference in activity [59]. To date,
there are 190 genetic variants in CYP1A2 [60,61]. An in silico study, by Wang et al. [52],
found 31 nonsynonymous SNPs, of which 24 were predicted to be deleterious by the SIFT
and PolyPhen algorithms. (S)-Methadone is marginally metabolized by CYP1A2 [46,62].
However, results of an in vitro study, conducted by Wang and DeVane [63], show neither the
depletion of (R)- and (S)-methadone, nor the formation of EDDP by recombinant CYP1A2.
Genetic variations in CYP1A2 did not affect or had little influence on the plasma
concentrations of methadone and EDDP [22,46,59]. Additionally, Crettol et al. [64]
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observed CYP1A2*1F did not influence (R)-, (S)-, or (R,S)-methadone at the peak or trough
levels in 245 MMT patients (96% white) (Table 1). Based on the current studies, CYP1A2
SNPs have not been shown to impact the metabolism of methadone.
3.2.

CYP2 family
The CYP2 family represents about 30% of human CYP isoforms, making it the largest CYP
family [65,66]. The liver is comprised of five drug metabolizing CYP2 subfamilies (A–E),
of which, the most pharmacologically important genes display the highest levels of
polymorphism [54,55]. Methadone is metabolized by several members of the CYP2 family:
2B6, 2C8, 2C9, 2C18, 2C19, and 2D6.

Author Manuscript

3.2.1. CYP2B—CYP2B6 has a 1–10% contribution to the total hepatic CYP pool,
accounting for the metabolism of about 7–8% of pharmaceutical drugs [54,59]. Despite this
enzymes’ relatively low involvement in drug metabolism, CYP2B6 is the predominant
determinant involved in the N-demethylation of methadone and clearance. CYP2B6 also
displays stereoselectivity towards (S)-methadone [46,67]. CYP2B6 is one of the most
polymorphic genes, having 70 allelic variants and 38 protein variants, which affect catalytic
activity, transcriptional regulation, and splicing. The variants also affect mRNA and protein
expression, exhibiting nearly 300 fold interindividual variability [54,60,68–71].

Author Manuscript

CYP2B6 SNPs can alter the metabolic ratios of [methadone]/[EDDP]. A significant decrease
in the metabolic ratio was observed in individuals carrying the CYP2B6*2 allele, suggesting
a role in an increased rate of metabolism. The data should be interpreted with caution
because the subjects heterozygous for the variant only had a sample size of two [72]. A
bioinformatics study also predicted CYP2B6*2 to alter the metabolic phenotype as
determined by both the SIFT and PolyPhen algorithms [52].
Lee et al. [73] studied the influence of CYP2B6*4 on methadone plasma concentrations in
178 MMT patients in Taiwan. The study indicated an increase in (R,S)-methadone plasma
levels in individuals homozygous for CYP2B6*4. The results were consistent with the
Levran et al. [74] study of 74 Israeli MMT patients; though neither study showed any
significant differences in the increase in (R,S)-methadone plasma levels. On the other hand,
Kharasch et al. [75] observed CYP2B6*4 carriers had a significant decrease in (R)-, (S)-,
and (R,S)-methadone plasma levels, with increased methadone metabolism and clearance. It
is important to note that one of the limitations to this study was the small sample size (n =
4). Gadel and colleagues [76] demonstrated an increase in N-demethylation of methadone by
CYP2B6*4 in an in vitro study, supporting the findings of Kharasch et al. [75].

Author Manuscript

CYP2B6*5 shows contradicting data in its involvement in methadone clearance and plasma
concentrations. In a genotyping study of methadone-only overdoses in 125 Caucasians,
CYP2B6*5 was linked to a significant increase in (R,S)-methadone plasma levels [72]. In a
study cohort consisting of 35 individuals with low (S)-methadone levels, CYP2B6*5 was
over-represented, indicating an increased CYP2B6 activity [32]. The methadone plasma
concentration of two individuals genotyped for homozygosity in CYP2B6*5 appeared to
remain unaltered when compared to that of the wild type CYP2B6*1 [75].
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CYP2B6*6 is a haplotype consisting of two nonsynonymous variants, CYP2B6*4 and
CYP2B6*9. Numerous papers indicate an increase in (R,S)- and (S)-methadone plasma
levels in CYP2B6*6/*6 individuals [64,67,75,77,78]. Gadel et al. [79] and Kharasch et al.
[75] have also demonstrated a decrease in methadone N-demethylation and decreased
methadone clearance, respectively. An in vitro study found SNPs CYP2B6*6 and
CYP2B6*9 to be catalytically deficient in EDDP formation [76]. Furthermore, increased
(R,S)-methadone plasma levels were observed in 74 Israeli MMT patients homozygous for
the CYP2B6*9 SNP, though the increase was not statistically significant [74]. A significant
increase in plasma concentrations and a decrease in (S)-methadone metabolism was
observed in 366 Taiwanese MMT patients encompassing the CYP2B6*9 SNP [80]. The
studies observing the SNPs of the haplotype CYP2B6*6 suggest that the diminishing
metabolic activity of CYP2B6*6/*6 is credited to the c.516G > T variant of CYP2B6*9.

Author Manuscript

Dobrinas et al. [32] observed an overrepresentation of CYP2B6*11 polymorphism in a high
(S)-methadone level group of MMT patients, indicating a decline in CYP2B6 activity. Wang
et al. [80] examined polymorphisms in the intronic and 3′-untranslated region (UTR)
regions of CYP2B6, and demonstrated the SNPs rs707265, rs2279345, rs1038376, and
rs10403955 all correspond to increased [(S)-methadone/methadone dose] plasma ratios, and
decreased (S)-methadone clearance (Table 1). The SNPs investigated in this section,
demonstrate a compelling link to the importance of genetic variations in CYP2B6 and
altered metabolism of methadone.

Author Manuscript

3.2.2. CYP2C—The CYP2C subfamily consists of four genes, CYP2C8, 2C9, 2C18, and
2C19. The CYPs from these genes all contribute to the metabolism of methadone
[46,77,81,82]. CYP2C9 is the highest expressed isozyme of the four in liver, while CYP2C8
and CYP2C19 are expressed at 2 and 10 fold lower levels than CYP2C9 [54]. CYP2C18 is
expressed primarily in the skin [59]. CYP2C19 comprises 16% of the CYP2C family and
metabolizes methadone to a greater extent, as compared to the CYP2C8, 2C9, and 2C18
isozymes [43]. The CYP2C family demonstrates stereoselectivity in methadone metabolism,
where CYP2C8 and 2C19 predominately metabolize (R)-methadone, while CYP2C18
primarily metabolizes (S)-methadone.
Currently, there are no polymorphic studies on CYP2C8 and 2C18 and their role in
methadone metabolism. This is not surprising for CYP2C18, where only 8 variants have
been reported to date [60,83]. There are 97 genetic variants observed in CYP2C8 [60,84],
which has a minor role in the metabolism of methadone, probably contributing to the dearth
of studies in the corresponding SNPs.

Author Manuscript

Although CYP2C9 exhibits 298 genetic variants and 2C19 has 111 reported genetic variants
[60,85], only *2 and *3 have been examined for their respective CYP isozymes. Results
from three separate studies showed no effect on methadone plasma levels with CYP2C9*2
and CYP2C9*3 genotypes in Caucasians [64,77,82]. A significant increase in methadone
serum concentrations/dose ratio with heterozygous carriers of CYP2C9*2 and CYP2C9*3
SNPs was observed in a study in Norway. Similar results were seen for the homozygous
CYP2C9*2 and CYP2C9*3 individuals, albeit, there was no significant differences in
methadone serum concentrations/dose ratios [78].
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In studies by Crettol et al. [64,77], CYP2C19*2 and CYP2C19*3 were also found to lack an
effect on methadone plasma levels. A study of 366 Taiwanese MMT patients showed
homozygous carriers of CYP2C19*2 were associated with a significant increase in (R)methadone levels. Patients homozygous for CYP2C19*3 also tended to exhibit an increase
in (R)-methadone levels, although the data was not significantly different [86]. Carlquist et
al. [87] observed an increase in the plasma levels of EDDP with CYP2C19*2 in 25 MMT
patients (20 Caucasian, 4 Hispanic, and 1 African American), indicating an increase in
methadone metabolism. Kringen et al. [78] noticed, in a Norwegian population, individuals
homozygous and heterozygous carriers for CYP2C19*2 and CYP2C19*3 had an increase in
methadone serum concentration/dose ratio, with significant differences seen only in
heterozygotes. The contradicting results in the CYP2C19 variants between these studies
could be attributed to the ethnicity of the patients, where the frequencies of both
CYP2C19*2 and CYP2C19*3 are higher in Asians than Caucasians (Table 1).
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3.2.3. CYP2D—The CYP2D subfamily consists of only one protein coding
gene,CYP2D6, which accounts for 2–5% of the hepatic CYP composition and ~25% of
pharmacological drug metabolism [54,88]. CYP2D6 metabolizes both enantiomers of
methadone, with a slightly greater propensity towards (S)-methadone [46,63]. Unlike SNPs
in other CYP genes, CYP2D6 phenotype is determined by allele combinations. PMs consist
of two non-functional alleles, IMs are comprised of two decreased activity alleles, EMs have
at least one functional allele, and UMs encompass more than one functional allele and/or an
allele with a promoter mutation [82]. The major and most common mutation alleles are
CYP2D6*3, *4, *5, and *6, accounting for 93–97% of alleles among PM phenotypes
[89,90]. CYP2D6*1 and CYP2D6*2 alleles represent normal functional activity.
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In a 2001 study conducted by Eap et al. [89], CYP2D6 phenotypes had a significant
influence on the (R)-, (S)-, and (R,S)-methadone blood concentrations, where higher
concentrations were observed in PMs (CYP2D6*4/*4, *4/*3, *4/*6) and lower
concentrations were measured in UMs (CYP2D6*1/*1). Similarly, Crettol and colleagues
[64], observed a 0.5 fold decrease in (S)-methadone and 0.7 fold decrease in (R)-methadone
plasma levels in UMs (CYP2D6*1/*1xN) when compared to the EM/IM (CYP2D6*1/*3,
*1/*4, *1/*5, *1/*6) group. In another study, the PM, IM, and EM phenotypes, representing
alleles CYP2D6*1, *1xN, *2, *3, *4, *4xN, *5, *6, *9, *10, *16, *28, *33, and *41, did not
impact the clearance of (R)-, (S)-, or (R,S)-methadone [91]. CYP2D6*3, *4, *5, *6, *7, and
*8 are non-functional variants, and CYP2D6*9, *10, and *41 have a decrease in function
[91]. Fonseca et al. [82] observed EM patients received significantly lower doses of
methadone as compared to UMs. It was also concluded that, contradictory to the
phenotypes, UM (CYP2D6*1xN,*2xN) patients had significantly higher methadone plasma
levels than EM (CYP2D6*1, *2, *3, *6, *35) and PM (CYP2D6*4/*4) patients. Further
investigations on the CYP2D6 alleles need to be conducted to get a clearer understanding of
their significance. The relationship between CYP2D6 allelic variants and phenotypic
expression is depicted in Table 2.
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The CYP3 family consists of only one subfamily, CYP3A, and four functional genes,
CYP3A4, 3A5, 3A7, and 3A43. These enzymes play a dominant role in drug metabolism
pathways (~50%). CYP3A4 is the most expressed enzyme in adult liver, while CYP3A7 is
predominantly expressed in fetal liver and is down-regulated after birth. CYP3A5 is
polymorphically expressed in the liver, where alternative splicing results in multiple
transcript variants, exhibiting high and low level proteins [54,88,92].
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Methadone has been shown to be N-demethylated by CYP3A4, 3A5, and 3A7 in a nonstereoselective manner [46,93]. CYP3A4 and CYP3A5 have relatively low numbers of
genetic variants, suggesting minor clinical importance in the clearance of their respective
substrates [59,74]. This observation would be in line with the lack of polymorphic studies
found for CYP3A and their role in methadone metabolism. However, in one study, the allelic
frequency of CYP3A4*1B in 245 MMT patients (96% white) was observed and correlated
with an increase in methadone plasma levels [64]. In the same study, the study cohort was
genotyped for the deficient allele CYP3A5*3. The plasma levels of methadone were not
influenced by the CYP3A5 genotype. It is also interesting to note that there was a strong
linkage between CYP3A4*1B and CYP3A5*3 genotypes [64]. Similar results were
observed by Fonseca et al. [82], where the genetic polymorphism of CYP3A5 did not
influence methadone plasma levels. One case report of a 25-year old male in a MMT
program showed extensive metabolism of methadone to EDDP. The subject was found to be
heterozygous for CYP3A5*1 (CYP3A5*1/*3) [94]. A large amount of CYP3A5 is
expressed in individuals carrying at least one CYP3A5*1 allele [94]. In a recent study of 155
serum samples and 62 patients, homozygous carriers of CYP3A5*3 demonstrated a
significant increase in methadone serum concentration/dose ratio, indicating a decrease in
methadone clearance [78] (Table 1).
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4.

Consequences of altered methadone metabolism
Polymorphisms in genes encoding CYP enzymes have the potential to shift their metabolic
capacity or change the substrate specificity of the enzyme, eliciting variable consequences in
drug treatment [95,96]. These changes can be crucial in the therapeutic potency of
methadone. The main metabolic pathway of methadone involves the N-demethylation by
hepatic CYPs into the primary metabolite, EDDP. Changes in the rate of EDDP formation
could influence the pharmacodynamics of methadone.
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CYP2B6*4 was the only SNP that was found to increase the clearance of methadone by the
N-demethylation of both (R)- and (S)-methadone [75,76]. In turn, there would be a decrease
in the disposition of (R,S)-methadone, reducing the pharmacological effect of methadone
and inducing withdrawal symptoms. Individuals with this SNP may require a higher dose of
methadone.
Several SNPs were found to increase the methadone plasma concentration due to a decrease
in the metabolic activity of the CYPs. Three independent studies collectively demonstrated
elevated plasma levels of (R,S)- and (S)-methadone with diminishing N-demethylation of
(R)- and (S)-methadone due to CYP2B6*2, *9 and *11 [32,72,74,76,80]. CYP2B6*6 is a
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haplotype consisting of both CYP2B6*4 and CYP2B6*9 variants. Carriers of CYP2B6*6/*6
had diminished methadone metabolism and clearance, hence, an increase in methadone
levels. This activity is credited to the CYP2B6*9 SNP, where individuals with
CYP2B6*4/*6 haplotype did not observe the metabolic inhibition [64,67,75–79]. Mutations
located in the UTR and intronic regions are also relevant in the biotransformation of
methadone. Table 1 shows the four SNPs in the UTR and intronic regions linked to a
decreased clearance and increased concentration of methadone [80]. CYP2B6 influences the
metabolism of (S)-methadone and, to a far lesser extent,(R)-methadone. Individuals with the
genotypes mentioned above, particularly CYP2B6*6/*6, have a greater risk of suffering
torsades de pointes and sudden death. A lower dose of methadone may be required for
treatment for individuals with these variants.
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Reduced metabolism by CYP2C19 can lead to increased plasma concentrations of
methadone, specifically (R)-methadone, which can potentiate depressed ventilation
manifesting as a potentially fatal respiratory depression. Both CYP2C19*2 and CYP2C19*3
were associated with elevated methadone plasma concentrations [78,86]. However, these
results could be variable in different ethnic groups.
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CYP2D6 and CYP3A4/5 metabolize both enantiomers of methadone, though CYP2D6 has a
slightly greater preference towards (S)-methadone. Decreased metabolism by these CYPs
may heighten either detrimental effect due to augmented levels of methadone. CYP3A4*1B
has been shown to increase (S)-methadone plasma levels [64], which can lead to cardiotoxic
effects. In a study of 136 Caucasian individuals who died of methadone-only overdosing, an
enrichment was observed in the CYP3A4*1B SNP [97]. CYP3A5*3 is a common SNP with
high frequency in the Caucasian population, where a splicing defect causes a loss of function
of the CYP3A5 enzyme [58]. This is exemplified in a couple of studies where the
methadone plasma levels are elevated in CYP3A5*3/*3 individuals, while metabolism is
increased and plasma levels are decreased in individuals carrying at least one copy of
CYP3A5*1 [79,94]. The effects of SNPs located on the CYP2D6 gene is slightly more
complicated. CYP2D6-dependent metabolism of methadone has been studied based on the
phenotypic variability determined by a combination of SNPs on the CYP2D6 gene. There
have not been any clear implications on the relationship between CYP2D6 SNPs and
methadone metabolism and their role on the pharmacokinetics and pharmacodynamics of
methadone.
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Since methadone is metabolized by a number of CYPs, a combination of any of the SNPs,
within or between genes, can have varying effects on the pharmacological response of
methadone treatment. A genome-wide pharmacogenomic study showed two CYP2B6
haplotypes of rs8100458, rs7250601, rs7250991, rs11882424, rs8192719, and rs10853744
(T-A-A-T-C-G and T-C-C-T-T-T) accounted for the variation in (S)-methadone plasma levels
[98]. In order to understand the complexity of the effects of CYP SNPs on methadone
pharmacokinetics and pharmacodynamics, inclusion of additional gene variants and haplotype variants is required. Though SNPs influence only part of methadone pharmacology, the
impact of genetic variations can be compounded by drug interactions, environmental factors,
sex, health, and other nongenetic factors. Co-administration of methadone with respiratory
depressants, such as other opioids, alcohol, or benzodiaze-pines, may lead to a greater
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detrimental effect. Likewise, individuals with reduced liver function (e.g. cirrhosis) could
have a reduced capacity to metabolize methadone.

5.

Conclusion

Author Manuscript

Methadone is currently used as a treatment and maintenance therapy for opioid addiction
and as an analgesic for severe chronic pain. The wide-ranging half-life of methadone may
result in some individuals having higher than normal therapeutic levels leading to negative,
detrimental, and fatal side effects. Elevated (R)-methadone levels may lead to respiratory
depression, while an increase in plasma levels of (S)-methadone may lead to severe cardiac
arrhythmias. A significant portion of opioid-related deaths have been contributed to the use
of prescription methadone for pain management. The pharmacogenetics of an individual
possesses the ability to affect the pharmacokinetics and pharmacodynamics of methadone.
SNPs located on CYP genes shift the metabolic capacity or change the substrate specificity
of the CYP enzyme, affecting the metabolism of methadone. SNPs CYP2B6*6, *9, *11,
CYP2C19*2, *3, CYP3A4*1B, and CYP3A5*3 result in increased methadone plasma
concentrations, decreased N-demethylation, and decreased methadone clearance. Since
CYP2B6 is the major determinant of methadone clearance, CYP2B6*6/*6 is of particular
interest. Homozygous carriers of CYP2B6*6/*6 expressed diminished methadone
metabolism and clearance, thus these individuals have a greater propensity for detrimental
adverse effects. However, CYP2B6*4 demonstrated an increase in N-demethylation and
methadone clearance. A better understanding of the role of CYP SNPs in methadone
metabolism can improve the proper therapeutic dosing for methadone, patient outcome, and
the development of individualized medicine.
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Abbreviations:
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ADH

alcohol dehydrogenase

CDC

Centers for Disease Control and Prevention

CYP

cytochrome P450

Del

deletion

EDDP

2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine

EM

extensive metabolizer

EMDP

2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline

FDA

Food and Drug Administration

hERG

human ether-a-go-go related gene

IM

intermediate metabolizer

MMT

methadone maintenance treatment

MOR

μ-opioid receptor
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MTD

methadone

NCBI

National Center for Biotechnology Information

p-HO

para-hydroxy

PM

poor metabolizer

SNP

single nucleotide polymorphism

UM

ultra-rapid metabolizer

UTR

untranslated region
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Fig. 1.

Eleven methadone metabolites found in human excretion. *Indicates chiral carbon atom.
ADH, alcohol dehydrogenase; CYP, cytochrome P450; EDDP, 2-ethyl-1,5-dimethyl-3,3diphenylpyrrolidine; EMDP, 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline; p-HO, parahydroxy.
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Table 1

Author Manuscript

Cytochrome P450 single nucleotide polymorphisms relevant to methadone metabolism.
Alleles

dbSNP ID†

Key sequence change‡

CYP1A2*1F

rs762551

intron 1, c.−9–154C >
A

CYP2B6*2

rs8192709

c.64C > T

CYP2B6*4

rs2279343

c.785A > G

Effect and key
amino acid
substitution (if
any)

Effect on enzyme activity

Ref.

No influence on (R)-, (S)-, or
(R,S)-MTD levels at trough or
peak

[64]

R22C

↑ [(R,S)-MTD]/[EDDP] ratio

[72]

K262R

↑ (R,S)-MTD plasma levels

[73,74]

↓ (R,S)-MTD plasma levels

[75,76]

↑ MTD clearance
↑ (R)- and (S)-MTD Ndemethylation

Author Manuscript

CYP2B6*5

rs3211371

c.1459C > T

R487C

↓ (S)-MTD plasma levels

[32]

↑ (S)-MTD clearance

CYP2B6*6

No effect on MTD clearance

[75]

↑ (R,S)-MTD plasma levels

[72]
[64,67,75–79]

rs2279343

c.785A > G

K262R

↑ (S)- and (R,S)-MTD plasma
levels

rs3745274

c.516G > T

Q172H

↑ MTD/Dose plasma ratio
↓ (R)- and (S)-MTD Ndemethylation
↓ MTD clearance

CYP2B6*9

rs3745274

c.516G > T

Q172H

↑ (R,S)-MTD plasma levels

[74,76,80]

↑ [(S)-MTD/MTD Dose] plasma
ratio

Author Manuscript

↓ (R)- and (S)-MTD Ndemethylation
↓ (S)-MTD clearance

CYP2B6*11

rs35303484

c.136A > G

M46V

↑ (S)-MTD plasma levels

[32]

↓ (S)-MTD clearance

CYP2B6 3′UTR

rs707265

↑ [(S)-MTD/MTD Dose] plasma
ratio

c.*1355A > G

[80]

↓ (S)-MTD clearance

CYP2B6 3′UTR

rslO38376

↑ [(S)-MTD/MTD Dose] plasma
ratio

3’UTR, c.*1277A > T

[80]

↓ (S)-MTD clearance

CYP2B6 intron 1

rsl0403955

↑ [(S)-MTD/MTD Dose] plasma
ratio

c.172–468 T > G

[80]

↓ (S)-MTD clearance

Author Manuscript

CYP2B6 intron 5

rs2279345

↑ [(S)-MTD/MTD Dose] plasma
ratio

c.923–197T > C

[80]

↓ (S)-MTD clearance

CYP2C9*2

CYP2C9*3

rsl799853

rsl057910

c.430C > T

c.1075A > C

R144C

I359L

No effect on MTD plasma levels

[64,77,82]

↑ MTD/Dose plasma ratio

[78]

No effect on MTD plasma levels

[64,77,82]
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Alleles

dbSNP ID†

Key sequence change‡

Effect and key
amino acid
substitution (if
any)

CYP2C19*2

rs4244285

c.681G > A

I331V; splicing defect

Effect on enzyme activity

Ref.

↑ MTD/Dose plasma ratio

[78]

No effect on MTD plasma levels

[64,77,82]

↑ (R)-MTD plasma levels

[78,86]

↑ MTD/Dose plasma ratio

CYP2C19*3

rs4986893

c.636G > A

CYP3A4*1B

rs2740574

5’UTR, C,
−392A > G

CYP3A5*3

rs776746

5’UTR,
c.219–237A > G

W212X; stop codon

Splicing defect

↑ EDDP plasma levels

[87]

No effect on MTD plasma levels

[64,77]

↑ MTD/Dose plasma ratio

[78]

↑ (S)-MTD plasma levels

[64]

No effect on MTD plasma levels

[64,82]

↑ MTD metabolism

[94]

Author Manuscript

(*1/*3 carrier)
↑ MTD/Dose plasma ratio
(*3/*3)
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee [69].
CYP, cytochrome P450; MTD, methadone; EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine; UTR, untranslated region.

†

National Center for Biotechnology Information (NCBI) dbSNP [88].

‡

Location of sequence change on mRNA for the respective CYP NM accession number [88].
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Table 2

Author Manuscript

Cytochrome P450 2D6 and their corresponding activity and phenotype.

Alleles

†

‡
Key sequence change

Effect and key
amino acid
substitution (if
any)

Effect on enzyme activity

Phenotype

Ref.

CYP2D6∗1

Wild type Duplication of
gene

EM

[57,64,82,89,91]

CYP2D6∗lxN

Multiduplication of gene

UM

[64,82,91]

EM

[57,82,89,91]

UM

[82]

dbSNP ID

N active genes
↑ activity

CYP2D6∗2

rsl6947

c.886C > T

R296C

Normal activity

rsl 135840

c.1457G > C

S486T

Duplication of gene

CYP2D6∗2xN

Multiduplication of gene

N active genes

Author Manuscript

↑ activity

CYP2D6∗3

rs3574686

c.775delA

259Frameshift

Defective allele

PM

[64,82,89,91]

CYP2D6∗4

rsl 065852

c.lOOC > T

P34S

Defective allele

PM

[57,64,82,89,91]

rs28371703

c.271C > A

L91M

rs28371704

c.281A > G

H94R

rs3892097

c.506–1G > A

Splicing defect

rsl 135840

c.1457G > C

S486T

CYP2D6∗4xN

Defective allele
Multiduplication of gene

PM

[91]

CYP2D6∗5

Deletion of entire CYP2D6
gene

PM

[57,64,91]

Author Manuscript

CYP2D6∗6

rs5030655

c.454delT

118Frameshift

Defective allele

PM

[64,82,89,91]

CYP2D6∗7

rs5030867

c.971A > C

H324P

Defective allele

PM

[91]

CYP2D6∗8

rs5030865

c.505G > A

G169R

Defective allele

PM

[91]

rsl 6947

c.886C > T

R296C

rsl 135840

c.1457G > C

S486T

CYP2D6∗9

rs5030656

c.841_843delAAG

K281del

Impaired function

IM

[91]

CYP2D6∗10

rsl 065852

c.lOOC > T

P34C

Impaired function

IM

[57,91]

rsl 135840

c.1457G > C

S486T

CYP2D7/2D6 hybrid

Frameshift;
switch region
exon7-intron 8

PM

[91]

rs28371706

c.320C > T

T107I

Impaired function

IM

[57]

rsl 6947

c.886C > T

R296C

rsl 135840

c.1457G > C

S486T

rs78482768

19G > A

V7M

Unknown

Unknown

[91]

rsl 6947

c.451C > G

Q151E

rsl 135840

c.886C > T

R296C

Impaired function

IM

[57]

CYP2D6∗16
CYP2D6H∗17

Author Manuscript

CYP2D6∗28

CYP2D6∗29

c.1457G > C

S486T

rs61736512

c.406G > A

V136I

rsl 6947

c.886C > T

R296C
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dbSNP ID

‡
Key sequence change

Effect and key
amino acid
substitution (if
any)

rs59421388

c.1012G > A

V338M

rsl 135840

c.1457G > C

S486T

CYP2D6∗33

rs28371717

c.709G > T

CYP2D6∗35

rs769258

c.31G > A

rsl 6947
rsl 135840

Alleles

Author Manuscript

CYP2D6∗36

CYP2D6∗41

†

Author Manuscript

Effect on enzyme activity

Phenotype

Ref.

A237S

Normal activity

EM

[91]

V11M

Normal activity

EM

[57,82]

c.886C > T

R296C

Duplication of gene

c.1457G > C

S486T

rsl 065852

c.lOOC > T

P34S

Defective allele

PM

[57]

rsl 135840

c.1457G > C

S486T

rsl 6947

c.886C > T

R296C

Impaired function

IM

[91]

rs28371725

c.985 + 39G > A

Splicing defect

Normal activity

EM

[57]

EM

[57]

rsl 135840

c.1457G > C

S486T

CYP2D6∗43

rs28371696

c.77G > A

R26H

CYP2D6∗45

rs28371710

c.463G > A

E155K

Normal activity

rsl 6947

c.886C > T

R296C

Duplication of gene

rsl 135840

c.1457G > C

S486T

Duplication of gene

More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee [69].
CYP, cytochrome P450; del, deletion; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra-rapid
metabolizer.

†

National Center for Biotechnology Information (NCBI) dbSNP [88].

‡

Location of sequence change on mRNA for the respective CYP NM accession number [88].
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